REDUSE trial enrolls 400th patient

Today the REDUSE trial reached a major milestone by randomizing its 400th patient. This achievement represents another important step toward improving treatment for patients with septic shock across international study sites.

The REDUSE trial is an international, randomized study evaluating whether a restrictive approach to fluid administration offers advantages over standard care. With 400 participants enrolled, the study remains on track to meet its target within the planned timeframe. This milestone will also enable the planned interim analysis to begin once 90-day follow-up data is available for all 400 participants.

The REDUSE team extends heartfelt thanks to all the patients, healthcare professionals, and research teams whose dedication and hard work have made this progress possible. Each contribution brings us closer to improving outcomes and saving lives.

Further updates will be shared as the REDUSE trial continues its critical work in advancing septic shock treatment.